What you should know:
1. The transaction is expected to close by April.
2. Pacira’s payment will include $120 million in cash up front and an additional $100 million upon achievement of commercial and regulatory milestones.
3. Under the agreement, Myoscience’s iovera will become part of Pacira’s portfolio.
4. Iovera freezes peripheral nerves through cryoneurolysis for opioid-free pain relief.
5. Last year, CMS approved separate payments to ASCs that use Pacira’s non-opioid pain management drug, Exparel.
More articles on supply chain:
SurgCenter Development forms 200th ASC partnership — Company in ‘full-growth mode’
Illinois community may benefit from ASC, OSF Regional Vice President says — 3 insights
How Southern California Orthopedic Institute shifted total joints to ASCs using bundled payments — 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
